Effect of the tyrosine kinase inhibitor nilotinib in patients with hypereosinophilic syndrome/chronic eosinophilic leukemia: analysis of the phase 2, open-label, single-arm A2101 study-Reference-Cited by-同舟云学术

Effect of the tyrosine kinase inhibitor nilotinib in patients with hypereosinophilic syndrome/chronic eosinophilic leukemia: analysis of the phase 2, open-label, single-arm A2101 study

Published:2013-09-22 Issue:12 Volume:139 Page:1985-1993
ISSN:0171-5216
Container-title:Journal of Cancer Research and Clinical Oncology
language:en
Short-container-title:J Cancer Res Clin Oncol

Author:

Hochhaus Andreas,le Coutre Philipp D.,Kantarjian Hagop M.,Baccarani Michele,Erben Philipp,Reiter Andreas,McCulloch Tracey,Fan Xiaolin,Novick Steven,Giles Francis J.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00432-013-1529-7.pdf

Reference49 articles.

1. Baccarani M, Cilloni D, Rondoni M, Ottaviani E, Messa F, Merante S et al (2007) The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study. Haematologica 92(9):1173–1179

2. Baumgartner C, Gleixner KV, Peter B, Ferenc V, Gruze A, Remsing Rix LL et al (2008) Dasatinib inhibits the growth and survival of neoplastic human eosinophils (EOL-1) through targeting of FIP1L1-PDGFRalpha. Exp Hematol 36(10):1244–1253

3. Buchdunger E, Matter A, Druker BJ (2001) Bcr-abl inhibition as a modality of CML therapeutics. Biochim Biophys Acta 1551(1):M11–M18

4. Butterfield JH (2009) Success of short-term, higher-dose imatinib mesylate to induce clinical response in FIP1L1-PDGFRalpha-negative hypereosinophilic syndrome. Leuk Res 33(8):1127–1129

5. Butterfield JH, Weiler CR (2012) Treatment of hypereosinophilic syndromes—the first 100 years. Semin Hematol 49(2):182–191

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment of eosinophilic and hypereosinophilic disorders;Allergic and Immunologic Diseases;2022

2. Eosinophilia characterized by a rare CCT6B mutation and responsive to tyrosine kinase inhibition: Case report and literature review;Leukemia Research Reports;2021

3. The Role of PDGFs and PDGFRs in Colorectal Cancer;Mediators of Inflammation;2017

4. Current Approach to Diagnosis and Management of Pulmonary Eosinophilic Syndromes: Eosinophilic Pneumonias, Eosinophilic Granulomatosis with Polyangiitis, and Hypereosinophilic Syndrome;Seminars in Respiratory and Critical Care Medicine;2016-05-27

5. The platelet-derived growth factors (PDGFs) and their receptors (PDGFRs) are major players in oncogenesis, drug resistance, and attractive oncologic targets in cancer;Growth Factors;2016-01-02